Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Mol Cancer Ther. 2010 Apr 13;9(5):1318–1327. doi: 10.1158/1535-7163.MCT-10-0069

Figure 4.

Figure 4

VX-680 eliminates Bcr/Abl kinase activities. BLQ1 (T315I mutation) and TXL2 (no mutation) cells were treated with the indicated concentrations of VX-680 with or without 100 nM dasatinib for 24 hrs. Western blot analysis was done on total lysates with the antibodies indicated to the left. Blots were stripped and reprobed with Bcr (N-20), Src and GAPDH antibodies as loading controls.